

Holmusk gets residency of Johnson & Johnson Innovation

08 January 2019 | News

Holmusk's team at JLABS @ NYC will focus on building the world's largest real-world evidence (RWE) platform for behavioral health



Holmusk became a resident company of Johnson & Johnson Innovation, JLABS (JLABS @ NYC), a premier life science incubator program. With its residency, Holmusk is excited to interact with other resident companies and looks forward to expanding its US footprint and deepening its relationship with partners and stakeholders within the pharma/life science hub of the US east coast.

Holmusk's team at JLABS @ NYC will focus on building the world's largest real-world evidence (RWE) platform for behavioral health. This platform will incorporate the latest evidence from clinical trials and real-world data, bringing insights to the point of care. Additionally, the platform will serve as a stepping stone to drive innovation among pharma companies to serve patients with unmet needs and allow quicker access to new drugs.

Holmusk is proud to be a part of JLABS @ NYC, which provides an ideal stage to interact with the life science ecosystem. "Being part of JLABS is like being part of a world class network of entrepreneurs and thought leaders - we are excited to join the conversation," said Holmusk's Founder and CEO Nawal Roy.

JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.